Western Australia dodges bullet as Soviet-built Kosmos 482 lands in Indian Ocean, ending 53 years in orbit
WA had a 'lucky escape' after it avoided being hit by a doomed Soviet spacecraft at the weekend, with the State at one point right in the firing line.
Kosmos 482 finally made its way out of orbit and back to Earth on Saturday after being launched by the Soviet Union in 1972.
According to EU Space Surveillance and Tracking, the spacecraft likely landed in the Indian Ocean west of Indonesia after 2pm Perth time, just 38,000,000km away from its planned destination of Venus.
While it appears the capsule ended up landing in the ocean, the uncontrolled nature of its re-entry meant there was a large degree of uncertainty as to where it would land, with some modelling predicting it could hit WA.
University of Western Australia Professor David Coward, one of two Australian signatories to the International Asteroid Warning Network, a UN-backed planetary defence organisation, said WA was almost in the firing line.
'It was a lucky escape, it's all about probability,' he said on Sunday.
'The satellite track, because the satellite orbits the Earth is every 90 minutes or so, follows a slightly different track, one of the tracks crossed Western Australia around Exmouth and then exited WA around Esperance.
'There was a real probability and in fact if this probe had a delayed re-entry it would have re-entered over WA and in fact only yesterday the best prediction for re-entry was over Western Australia.'
Encased in titanium and weighing in at almost half a tonne, Kosmos 482 was a landing module which never left orbit due to a malfunction of the launch vehicle.
Professor Coward said the chances of the craft hitting a suburban area was always slim but the impact if it did could have been deadly.
'If it actually re-entered over a city, there could be a fatality,' he said.
'The probability of it actually causing injuries is quite remote, mainly because of the vastness of the land mass compared to the size of the satellite.
'The satellite would essentially be like a bullet, it travels at what's called terminal velocity which is hundreds of kilometres a second so it would have formed a crater.
'There would have been a small explosion, because the body is about a metre if I recall in size so it would have been like a projectile coming down from space.'
According to Professor Coward international rules state the launcher of spacecrafts are responsible for collecting any space junk that returns onto Earth but it is unclear yet whether Kosmos 482 would be retrievable as it may have sunk to the bottom of the ocean.
Perth Observatory's Matt Woods said WA was a magnet for space junk.
In 2023, an old Indian rocket washed up on a beach in Green Head. And in 1979, Sky Lab famously plummeted back to Earth and crashed near Esperance.
'(Kosmos 482) was designed to survive the atmosphere, so you don't really want that falling on you at any time,' Mr Woods said.
'This one was kind of rare in the sense that it was a failed mission to Venus, it just never escaped Earth's atmosphere,' he said.
'Basically what ended up happening was it just orbited around the Earth for ages until the orbit decayed so much that it came back after 50 years.
'But we do get a lot of space junk hitting our atmosphere and burning up in the atmosphere.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Perth Now
37 minutes ago
- Perth Now
Regional students to capture the sun in science program
Students at two schools near major renewable energy projects will be challenged to create solar-powered toy cars and design sustainable houses in bid to foster science education in regional areas. Major energy retailer Alinta and the Australian Academy of Technical Science and Engineering launched their partnership on Monday, revealing an extension to the STELR education program for schools in NSW and South Australia. The announcement comes days after Women 4 STEM called for greater funding to encourage students to study science, technology engineering and maths in regional areas, amid fears artificial intelligence technology could disadvantage girls in particular. Alinta will fund science kits for students at Melville High School near its Oven Mountain pumped hydro project in NSW, and at Gawler and District College in South Australia, near its Reeves Plains battery storage hub. The schools were chosen for their proximity to renewable energy projects to foster curiosity about jobs in the growing future industry, Alinta chief executive Jeff Dimery said. "It's about creating real connections between students, their communities and the future of energy," Mr Dimery said. "By supporting schools near our future renewable energy sites, we're helping young people see themselves in the energy transition and giving them the tools to be part of it." The energy firm will also provide in-person training for teachers, in addition to online resources and renewable energy kits that include mini solar panels and houses. The STELR program, which began in 2008, has reached more than one million Australian students. Teaching children science in a practical way would be vital to support the next generation of energy workers, academy chief executive Kylie Walker said. "To effectively transition Australia's energy towards low-carbon and zero-carbon solutions, it's urgent that we educate and inspire school students and empower them to make the most of the careers of the future," she said. "Supporting hands-on science, technology and engineering education in schools benefits students, teachers, society and the economy by building the skills, capability and motivations of the highly capable professionals who will deliver the energy projects of the future." A federal Education Department study found 15-year-olds in remote areas of Australia were 1.5 years behind their urban peers in science studies on average, and performed significantly below the international average in mathematics. Challenges identified by the research included limited access to resources and difficulty finding and retaining qualified science teachers.
The Advertiser
a day ago
- The Advertiser
'Game changer' diabetes pill a step closer after trials
Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues. That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar. Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine. "It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP. "The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro." The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend. Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns. The trial focused on diabetes treatment and not specifically weight loss. Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said. He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro. The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments. "These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said. "In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world." Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections. While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar. "As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said. Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug. Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues. That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar. Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine. "It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP. "The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro." The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend. Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns. The trial focused on diabetes treatment and not specifically weight loss. Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said. He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro. The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments. "These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said. "In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world." Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections. While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar. "As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said. Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug. Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues. That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar. Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine. "It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP. "The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro." The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend. Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns. The trial focused on diabetes treatment and not specifically weight loss. Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said. He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro. The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments. "These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said. "In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world." Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections. While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar. "As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said. Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug. Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues. That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar. Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine. "It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP. "The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro." The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend. Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns. The trial focused on diabetes treatment and not specifically weight loss. Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said. He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro. The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments. "These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said. "In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world." Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections. While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar. "As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said. Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug.
West Australian
a day ago
- West Australian
'Game changer' diabetes pill a step closer after trials
Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues. That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar. Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine. "It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP. "The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro." The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend. Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns. The trial focused on diabetes treatment and not specifically weight loss. Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said. He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro. The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments. "These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said. "In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world." Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections. While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar. "As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said. Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug.
